Four-Strain Flu Vaccine Gains Traction With Sanofi’s sBLA Filing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi’s application for a quadrivalent flu vaccine comes eight months after FDA approved MedImmune’s quadrivalent and seven months after GSK’s filing; companies expect to transition to the four-strain vaccine.